Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LONDON, May 28, 2026 (GLOBE NEWSWIRE) -- TREOS Bio, a clinical-stage biotechnology company developing next-generation off-the-shelf peptide cancer immunotherapies, supported by biomarker-guided...
-
UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapyTGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that...
-
Orphan Drug Designation confers regulatory, financial and strategic advantagesEO2463 has shown potentially disease modifying activity in clinical testing in watch-and-wait iNHL patientsEO2463 has...
-
UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapyTGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that...
-
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
-
Liver disease is often found late because people have no symptoms. This research shows how using existing NHS blood test data could help change that.
-
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...
-
STORM Therapeutics announces that a subset analysis of sarcoma patients enrolled in the Phase 1 dose escalation study of STC-15 will be presented at ASCO.
-
REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
-
Austin, TX, USA, May 21, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Genome Editing Market Size, Trends and Insights By Technology (CRISPR)/Cas9,...